I really like the phrase "significantly slows disability progression".
Masitinib Slows Disability Progression in PPMS, Non-active SPMS
"Masitinib, AB Science’s experimental oral therapy, significantly slows disability progression in adults with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS), according to final data from the AB07002 Phase 2b/3 clinical trial."
Masitinib Slows Disability Progression in PPMS, Non-active SPMS (multiplesclerosisnewstoday.com)
Masitinib Slows Disability Progression in PPMS, Non-active SPMS
"Masitinib, AB Science’s experimental oral therapy, significantly slows disability progression in adults with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS), according to final data from the AB07002 Phase 2b/3 clinical trial."
Masitinib Slows Disability Progression in PPMS, Non-active SPMS (multiplesclerosisnewstoday.com)
Comment